Article
- Author:
- Philip G. Janicak, MD
Publish date: October 1, 2021
Despite considerable challenges, prevention and first-episode recovery programs may improve outcomes.
Article
- Author:
- Philip G. Janicak, MD
Publish date: October 1, 2021
SECOND OF 2 PARTS
Options include OTC agents, anti-inflammatory/immune system therapies, and devices.
Article
- Author:
- Philip G. Janicak, MD
Publish date: September 1, 2021
FIRST OF 2 PARTS
Some off-label agents show promise, but carry risks.
Article
- Author:
- Philip G. Janicak, MD
Publish date: March 1, 2019
Recent developments have enhanced the benefits of this treatment.
Article
- Author:
- Philip G. Janicak, MD
Publish date: May 26, 2016
The utility of TMS for treating depression continues to widen, as the technology is refined
Article
- Author:
- Philip G. Janicak, MD
Publish date: November 1, 2010
Recent developments have revived interest in brain stimulation for difficult-to-treat patients
News
- Author:
- Philip G. Janicak, MD
Publish date: September 1, 2007
Risperidone’s metabolite behaves well but differently in once-daily delivery.
News
- Author:
- Philip G. Janicak, MD
Publish date: September 1, 2005
Surgical option for treatment-resistant depression
News
- Author:
- Philip G. Janicak, MD
Publish date: June 1, 2003
Despite early mixed results, magnetic stimulation of the prefrontal cortex is showing potential in major depression and other psychiatric disorder...
Article
- Author:
- Philip G. Janicak, MD
Publish date: January 1, 2002
Neuroleptics have played an important but controversial role in mood disorder treatment. Novel antipsychotic agents may represent a significant dep...
